PTSD Trial, Recruiting NCT07568145 Sponsor: Emory University Condition: PTSD
Back to Ptsd

PTSD Trial, Recruiting

NCT07568145
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 65 years old
  • People who have experienced a traumatic event — such as something that involved death, serious injury, or sexual violence — within the last 2 weeks
  • People who are currently experiencing high levels of PTSD symptoms related to that recent trauma, as measured by a standard questionnaire and symptom checklist
  • People who have experienced a previous trauma in their lifetime but are currently showing low levels of PTSD symptoms related to that earlier event
  • People who are currently taking psychiatric medications (such as antidepressants, antipsychotics, benzodiazepines, or anticonvulsants), as long as the dose has been stable for at least 6 weeks and will not change during the study
  • People who are able and willing to give their informed consent to participate

Who may not be able to join:

  • People who currently have thoughts of suicide with a plan or intent, or where a clinician judges there to be a likely risk of a suicide attempt in the next six months
  • People who have ever been diagnosed with a psychotic disorder or bipolar disorder
  • People who have been diagnosed with a neurological condition — such as epilepsy or a history of seizures, stroke, a brain tumour, cerebrovascular disease, a cerebral aneurysm, or a movement disorder — or who have ever lost consciousness for more than 5 minutes due to a head injury
  • People who have had brain surgery, or who have metal particles in the eye or head (not including the mouth), a pacemaker or any lines inside the heart, implanted nerve stimulators, implants inside the skull (such as aneurysm clips, shunts, cochlear implants, or electrodes), or implanted medication pumps
  • Women who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sanne van Rooij, PhD, Emory University

Phone: 404-251-8926

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 June 2026
Est. completion
1 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Amygdala Reactivity During Fear Processing Pre- to Post TMS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov